secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syra Health Corp (SYRA)
CIK:        0001922335
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001493152-25-028301
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syra Health appoints Gregory R. Alexander as CEO effective Jan 5, 2026
----------------------------------------------------------------------

- New CEO Gregory R. Alexander receives $251k base salary, 30% target bonus, and 110,537 RSUs.
- Also granted 257,920 stock options (Class B) and 368,458 performance stock units.
- Alexander previously served as SVP at Ellipsis Health, Chief Growth Officer at CitizensRx (tripled sales), and market leader at Lumeris (expanded from 3 to 11 markets).
- He will replace interim CEO Priya Prasad; appointment follows an extensive national search.
- Alexander is a former U.S. Marine Corps officer with over 20 years of P&L experience in healthcare.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1922335/000149315225028301/0001493152-25-028301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1922335/000149315225028301/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-028301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer